Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSSM 001

X
Drug Profile

OSSM 001

Alternative Names: CHYMALIS; Chymelis; Mesenchymal stem cell therapy - Ossium Health; Ossium vBM-MSC; OSSM-001

Latest Information Update: 03 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ossium Health
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • Research Radiation injuries

Most Recent Events

  • 23 Dec 2022 Ossium Health withdraws a phase I trial prior to enrolment in Graft versus host disease (IV, Infusion) due to the reason that OSSM 001 will not be used in this program moving forward (NCT05443464)
  • 21 Dec 2022 Ossium Health withdraws a phase I trial prior to enrolment in Crohn's disease (In adults, In the elderly) (Parenteral, Injection) due to the reason that OSSM 001 will not be used in this clinical program (NCT05407766)
  • 05 Jul 2022 Ossium Health plans a phase I trial for Graft versus host disease in June 2023 (IV, Infusion) (NCT05443464)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top